Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$5.01 USD
+0.46 (10.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.99 -0.02 (-0.40%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.01 USD
+0.46 (10.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.99 -0.02 (-0.40%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma (STRO) delivered earnings and revenue surprises of 22.37% and 2.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
XOMA Royalty (XOMA) delivered earnings and revenue surprises of -7.69% and 32.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Repare Therapeutics (RPTX) delivered earnings and revenue surprises of 3.53% and 73.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -0.96% and 7.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 37.84% and 1.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Sutro Biopharma (STRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
by Zacks Equity Research
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 12.33% and 0.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -31.82% and 44.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to Buy
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 8.43% and 11.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?